Pacing fault halts Guidant's Ventak AV sales
This article was originally published in Clinica
Executive Summary
Guidant has suspended shipments of its Ventak AV implantable cardioverter defibrillator (ICD) after it failed to pace correctly in undisclosed number of patients. Ventak AV is the company's latest ICD and offers dual chamber pacing in addition to defibrillation. Defibrillation is not affected by the problem.
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.